摘要
目的:探讨自发性气胸胸管内注入设定药物与气胸复发、住院天数及医疗费用的相关性。方法:对60例自发性气胸患者,胸腔闭式引流后X线检查证实肺基本复张后,随机分为对照组(单纯胸腔闭式引流),治疗组(经胸管内注入利多卡因、高渗糖及重组人白介素-2)。随访2～10年。结果:治疗组治愈28例,复发2例,总有效率95%,复发率6%,住院天数平均(10±1)d,住院费用(4000±316)元。对照组患者治愈16例,14例复发,总有效率53%,复发率为46%,住院平均天数为(18±2)d,费用(8000±615)元。两组比较,有效率、复发率、住院天数及住院费用均差异有统计学意义(P<0.01)。结论:利多卡因、高渗糖及重组人白介素-α联合胸腔内注入是治疗及预防复发、减少副作用、缩短住院时间、降低医疗费用的有效方法。
Objective：To investigate the relationship between chest tube injected in setting drug and recurrence of pneumothorax,hospital stays,and hospitalization costs in patients with spontaneous pneumothorax. Method：60 patients suffering from spantaneous pneumothorax with chest tube injected were included. After lungs recruitment,60 patients were randomly assigned either a treatment program that included intraluminal injection of Lidocaine heperosmotic glucose and recombinant Human IL-2 or one that only used thoracic close drainage therapy. Follow up for 2-10 years. Result： In the treatment group,the patients who recovered accounted for 95%（28 cases）,and relapsed for 6%（2 cases）. The mean hospital stay and hospital costs were 10 days,and 4000 yuan,respectively. While in the control group,the cure rates and recurrence rates were 53%（16 cases）,and 46%（14 cases）,respectively. The mean hospital stay was 18 days,and the hospital cost was 8000 yuan. Conclusion：There was statistically significant effect that using intraluminal injection of Lidocaine,heperosmotic glucose and recombinant Human IL-2 to treatment and prevention of recurrence for the spantaneous pneumothorax,reduce side effects,shorter hospital stays,lower medical costs.
出处
《中国医学创新》
CAS
2013年第24期115-116,共2页
Medical Innovation of China
关键词
自发性气胸
胸腔闭式引流
胸膜粘连固定
复发
住院时间
医疗费用
Spontaneous pneumothorax
Thoracic close drainage
Pleural adhesion fixed
Recurrence
Hospital stays
Hospitalization costs
